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From the ‡Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona 85013 and the §Department of
Pharmacology/Toxicology and ¶Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia 23298
Background: The naturally occurring ␣5(D398N) variant alters smoking behavior, but functional differences have not been
detected between ␣3␤4␣5 nAChR harboring these variants.
Results: ACh-induced ␣3␤4␣5 nAChR function is lower when ␣5(Asn-398) substitutes for ␣5(Asp-398).
Conclusion: The ␣5 variant-induced change in ␣3␤4␣5 nAChR function may underlie some of the phenotypic changes associated with this polymorphism.
Significance: ␣3␤4␣5 nAChR function may be a useful target for smoking cessation pharmacotherapies.

Nicotinic acetylcholine receptors (nAChR)2 are prototypical
members of the ligand-gated ion channel superfamily of neu-
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rotransmitter receptors. nAChR exist as a diverse family of
molecules composed of different pentameric combinations of
homologous subunits derived from at least 17 genes (␣1-␣10,
␤1-␤4, ␥, ␦, ⑀). The properties of nAChR are determined by
their subunit composition, giving rise to multiple subtypes with
a range of overlapping pharmacological and biophysical properties (1). It also has become apparent that different stoichiometries of the same subunits can produce subtypes with distinctly
different characteristics, a phenomenon observed in both heterologous and natural expression systems (1–5).
Recently, genome-wide association studies have indicated
that single-nucleotide polymorphisms (SNPs) within nAChR
subunits can substantially affect nAChR-mediated smoking
behavior in humans. Most prominent among these single-nucleotide polymorphisms have been those located in the
CHRNA5/CHRNA3/CHRNB4 locus, located on chromosome
15q25, which encodes the ␣5, ␣3 and ␤4 subunits of nicotinic
receptors. This locus was first associated with nicotine dependence (6). Subsequent studies confirmed associations of singlenucleotide polymorphisms at this locus with heavy smoking
(⬎25 cigarettes smoked daily), Fagerström Test for Nicotine
Dependence scores and age dependent severity of nicotine
dependence (7–11). One non-synonymous polymorphism
(rs16969968), which changes the 398th amino acid from aspartic acid to asparagine (D398N) in the ␣5 subunit, is particularly
strongly associated with greater risk for increased nicotine consumption. Interestingly, variants at this locus also are associated with increased liability for lung cancer (8, 12, 13), and
possibly with decreased risk for alcoholism (7, 14) and cocaine
dependence (15).
These observations raise the question of what the functional
effects of the D398N mutation might be. The ␣5 subunit can
only assemble into functional nAChR when expressed with at
least two other subunits (1). In the central nervous system, most
␣5 subunit expression occurs in combination with ␣4 and ␤2
subunits (16, 17). Experiments using heterologous expression
systems have demonstrated that ␣4␤2* nAChR containing ␣5
subunits harboring the risk (Asn-398) variant have lower function than those that incorporate ␣5 subunits with the common
(Asp-398) variant (11, 18). This provides a mechanism through
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Genome-wide studies have strongly associated a non-synonymous polymorphism (rs16969968) that changes the 398th
amino acid in the nAChR ␣5 subunit from aspartic acid to asparagine (D398N), with greater risk for increased nicotine consumption. We have used a pentameric concatemer approach to
express defined and consistent populations of ␣3␤4␣5 nAChR
in Xenopus oocytes. ␣5(Asn-398; risk) variant incorporation
reduces ACh-evoked function compared with inclusion of the
common ␣5(Asp-398) variant without altering agonist or antagonist potencies. Unlinked ␣3, ␤4, and ␣5 subunits assemble to
form a uniform nAChR population with pharmacological properties matching those of concatemeric ␣3␤4* nAChRs. ␣5 subunit incorporation reduces ␣3␤4* nAChR function after coinjection with unlinked ␣3 and ␤4 subunits but increases that of
␣3␤4␣5 versus ␣3␤4-only concatemers. ␣5 subunit incorporation into ␣3␤4* nAChR also alters the relative efficacies of
competitive agonists and changes the potency of the non-competitive antagonist mecamylamine. Additional observations
indicated that in the absence of ␣5 subunits, free ␣3 and ␤4
subunits form at least two further subtypes. The pharmacological profiles of these free subunit ␣3␤4-only subtypes are dissimilar both to each other and to those of ␣3␤4␣5 nAChR. The ␣5
variant-induced change in ␣3␤4␣5 nAChR function may
underlie some of the phenotypic changes associated with this
polymorphism.

␣5(D398N) Effects on ␣3␤4 Nicotinic Receptor Function

EXPERIMENTAL PROCEDURES
Chemicals—All buffer components and pharmacological
reagents (acetylcholine, atropine, cytisine, nicotine, and
mecamylamine) were purchased from Sigma. Fresh stock drug
solutions were made daily and diluted as required.
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Constructs for Individual ␣3, ␤4, and ␣5 nAChR Subunits—
Native human subunit protein sequences for ␣3, ␤4, and ␣5
(both Asn-398 and Asp-398 variants) nAChR subtypes were
encoded by nucleotide sequences optimized for expression in
vertebrate expression systems (synthesized by GeneArt AG;
Invitrogen). Optimizations included minimization of high GC
content sequence segments, improved codon usage, reduction
of predicted RNA secondary structure formation, and removal
of sequence repeats and possible alternative start and splice
sites. Sequences were subcloned into the pSGEM oocyte high
expression vector (a kind gift of Prof. Michael Hollmann; RuhrUniversitaet, Bochum, Germany).
Concatemeric ␣3␤4 and ␣3␤4␣5 Constructs—Fully pentameric nAChR concatemers were constructed from human
nAChR subunits. cDNAs encoding concatemers were created
using the same subunit layout as successfully used to encode
high and low agonist sensitivity ␣4␤2* nAChR isoforms (5).
Subunits were arranged in the order ␤4-␣3-␤4-␣3-X, where X
was either ␤4, ␣3, ␣5(Asp-398) or ␣5(Asn-398); Fig. 1A. Kozac
and signal peptide sequences were removed from all subunit
sequences with the exception of subunits expressed in the first
position of the concatemer. As previously demonstrated, the
initial ␤-␣ subunit protein pairs of the constructs will assemble
to form an orthosteric binding site between the complementary
(⫺) face of the initial ␤4 subunit and the principal (⫹) face of
the following ␣3 subunit (4). The assembled ␣3␤4* nAChR
concatemers thus contain orthosteric agonist binding pockets
at the ␤4(⫺)/(⫹)␣3 interfaces between the first and second and
between the third and fourth subunits (5). As for individual
subunits, native human subunit protein sequences were
encoded by nucleotide sequences optimized for expression in
vertebrate expression systems (synthesized by GeneArt AG).
Optimizations fell in the same categories as those previously
described. Subunits were linked by alanine-glycine-serine
(AGS) repeats designed to provide a complete linker length
(including the C-terminal tail of the preceding subunit) of 40 ⫾
2 amino acids. At the nucleotide level, linker sequences were
designed to contain unique restriction sites that allow easy
removal and replacement of individual ␣3, ␤4, and ␣5 subunits
(Fig. 1A). Sequences of all subunits together with their associated partial linkers were confirmed by DNA sequencing
(Geneart AG). Each concatemer was subcloned into the
pSGEM oocyte high expression vector. Correct assembly of the
concatemers into the expression vector was verified by restriction digest (Fig. 1, A and B). Additionally, concatemers were
digested with ScaI to further diagnose the stoichiometry of each
construct (* as indicated; Fig. 1B).
RNA Synthesis—Plasmids containing single ␣3, ␤4, or ␣5
(Asn-398 and Asp-398 variants) nAChR subunits or ␣3␤4 and
␣3␤4␣5 concatemeric constructs were linearized with NheI (2
h at 37 °C) and treated with proteinase K (30 min at 50 °C).
cRNAs were transcribed using mMessage mMachine T7 kit
(Applied Biosystems/Ambion, Austin, TX). Reactions were
treated with TURBO DNase (1 unit for 15 min at 37 °C), and
cRNAs were purified using Qiagen RNeasy Clean-up kit
(Valencia, CA). cRNA purity was confirmed on a 1% agarose gel
(Fig. 1B), and preparations were stored at ⫺80 °C.
VOLUME 287 • NUMBER 30 • JULY 20, 2012

Downloaded from http://www.jbc.org/ at ELSEVIER BV on September 19, 2019

which the ␣5(D398N) mutation could produce phenotypic
effects. Notably, a restricted set of brain regions (most prominently in the habenuolopeduncular pathway) express ␣5 subunits in combination with ␣3 and ␤4 subunits (19, 20), as often
occurs in autonomic ␣3␤4* nAChR (21–23). A recent study
showed that increased expression of ␣3␤4* nAChR in the habenulopeduncular tract of mice increases nicotine aversion, an
effect that can be reduced by the introduction and expression of
additional ␣5(Asn-398) subunits in the same pathway (20). Furthermore, ␣3, ␤4, and ␣5 nAChR subunits are commonly
expressed in bronchial, epithelial, and lung cancer cells, where
nAChR activation by nicotine has been proposed as a mechanism that may increase tumor initiation and/or growth (24).
However, heterologous expression studies done to date have
not identified functional differences induced by ␣5 variant
incorporation into ␣3␤4* nAChR (18, 25).
Other observations may help to explain this discrepancy
between in vitro observations and in vivo phenotypes. It has
been shown that ␣3␤4 nAChR can be expressed in multiple
stoichiometries, with different functional properties (26 –28).
Moreover, ␣5 subunits can “compete” with ␤4 subunits for
incorporation into assembled nAChR (29), possibly forcing formation of non-functional nAChR subunit assemblies as “dead
end intermediates” (30). Thus, the effect(s) of common ␣5(Asp398) versus risk ␣5(Asn-398) variant subunit incorporation into
␣3␤4* nAChR may be obscured by changes, attendant on any
␣5 subunit incorporation, in the overall level of ␣3␤4 nAChR
functional expression and/or the balance of functional stoichiometric isoforms expressed. This complication in experimental
interpretation is compounded when various mixtures of
nAChR subtypes with specific subunit ratios are expressed
from “loose” subunits assembled under host cell, and not investigator, control.
To overcome these difficulties in interpretation, we employed a concatemeric nAChR approach (Fig. 1). Here, nAChR
constructs are assembled that encode all five subunits of the
desired ␣3␤4* nAChR subtypes joined by short peptide linkers.
The advantage of this approach is that complex nAChR subtypes can be expressed with native nAChR-like properties and
with completely defined subunit ratios and orders of assembly
(5, 31). Using concatemeric ␣3␤4␣5 nAChR, we demonstrate
that, as is true for ␣4␤2* nAChR, incorporation of the ␣5(Asn398) variant reduces maximal acetylcholine-induced function
when compared with the ␣5(Asp-398) variant. The properties
of the defined concatemeric nAChR also were compared with
those of ␣3␤4* nAChR allowed to assemble freely from loose
individual subunits. These comparisons confirmed that concatemeric and freely assembled ␣3␤4␣5 nAChR have essentially indistinguishable pharmacological properties. Interestingly, these comparisons also suggested that loose ␣3 and ␤4
subunits associate quite differently in the presence or absence
of ␣5 subunits.

␣5(D398N) Effects on ␣3␤4 Nicotinic Receptor Function

Oocyte Preparation and RNA Injection—Methods of oocyte
isolation and processing for receptor expression have previously been described (32, 33) but were modified as follows.
Lobes were digested with 0.75 units/ml LiberaseTM (Roche
Applied Science), and oocytes were incubated at 13 °C. The tips
of pulled glass micropipettes were broken to achieve an outer
diameter of ⬃40 m (resistance of 2– 6 milliohms), and
pipettes were used to inject 20 – 60 nl containing 10 ng of
cRNA/oocyte.
Expression of ␣3␤4 and ␣3␤4␣5 Constructs in Xenopus
Oocytes—Seven days after injection, Xenopus oocytes expressing loose ␣3 and ␤4 with or without ␣5 (Asn-398 and Asp-398
JULY 20, 2012 • VOLUME 287 • NUMBER 30

variants) subunits from individual cRNAs at the indicated
ratios or ␣3␤4 and ␣3␤4␣5 concatemers were voltage-clamped
at ⫺70 mV with an Axoclamp 900A amplifier (Molecular
Devices, Sunnyvale, CA). Recordings were sampled at 10 kHz
(low-pass Bessel filter, 40 Hz; high pass filter, DC), and the
resulting traces were saved to disk (Molecular Devices Clampex
v10.2). Data from oocytes with leak currents (Ileak) ⬎50 nA were
excluded from recordings. Known nAChR agonists and antagonists were applied using a 16 channel, gravity-fed, perfusion
system with automated valve control (AutoMate Scientific,
Inc.; Berkeley, CA). All solutions contained atropine sulfate (1.5
M) to ensure that muscarinic responses were not recorded.
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 1. Linked (concatemeric) subunit design of ␣3␤4␣5 receptors. A, shown is a schematic illustration of (from top to bottom) ␤4␣3␤4␣3␤4,
␤4␣3␤4␣3␣3, ␤4␣3␤4␣3␣5(Asp-398), and ␤4␣3␤4␣3␣5(Asn-398) constructs. Each construct is flanked with AscI and EcoRV restriction sites (5⬘ and 3⬘,
respectively; indicated by gray circles) for subcloning into high expression oocyte vectors. Kozac and the ␤4 signal peptide (SP) were retained only for the 1st
position. Flanking each subunit position are unique restriction sites (indicated by gray circles) used in concatemer design (for example, AscI and XbaI used in
exchanging nAChR subunits at position 1; XbaI and AgeI sites were used in exchanging nAChR subunits at position 2; etc.). Concatemers varied in composition
only at position 5, containing either the ␤4, ␣3, or two naturally occurring variants of the ␣5 nAChR subunit (aspartic acid (Asp-398) or asparagine (Asn-398)).
Stop codons (SC) were added at the 3⬘ end of subunit position 5. The number of AGS repeats flanking each subunit is listed below each linker region. B, shown
is stoichiometry of ␤4␣3␤4␣3␤4, ␤4␣3␤4␣3␣3, ␤4␣3␤4␣3␣5(Asp-398), and ␤4␣3␤4␣3␣5(Asn-398) constructs. Concatemers form pentameric receptors by
joining the positive interface of the nAChR subunit at position 1 (P1) and the negative interface of position 5 (P5). Restriction digest (below each schematic)
using unique restriction sites (as mentioned above) was used to verify each subunit within its respective position (P1-P5). An additional restriction digest (*)
using ScaI was performed to diagnose correct subunit composition and order. M, molecular mass markers.

␣5(D398N) Effects on ␣3␤4 Nicotinic Receptor Function

Oocytes-expressing loose subunits and/or concatemeric
␣3␤4␣5 nAChR were perfused with receptor agonist (e.g. ACh,
cytisine, and nicotine) or antagonist (e.g. mecamylamine) for 5 s
with 60 s washout times between each subsequent application
of drug.
Data Analysis—EC50 or IC50 values and peak current amplitudes (Imax) were determined from individual oocytes. All stimulation protocols began with stimulation by a maximally efficacious dose of ACh (1 mM). This ensured that oocytes were
indeed expressing functional nAChR before we did further
recording, and it provided an internal control response for each
oocyte. Relative agonist efficacies were calculated by comparison to this internal ACh control response. EC50 and IC50 values
were determined through non-linear least squares curve-fitting
(GraphPad Prism 4.0, GraphPad Software, Inc., La Jolla, CA)
using unconstrained, monophasic logistic equations to fit all
parameters, including Hill slopes. Additional normalization
was used to compare absolute agonist efficacy between the concatemeric nAChR constructs. As for the nAChR expressed
from loose subunits, all peak current response data were collected at 7 days post-injection. Function produced by oocytes
expressing (␣3␤4)2␣5(Asp-398) concatemers was chosen as the
internal reference point for each batch of injected oocytes, as
␣5(Asp-398) is the more-common variant. Responses to 1 mM
ACh, which is a maximally effective concentration for all of the
constructs studied here, were measured. The mean function
produced by oocytes injected with (␣3␤4)2␣5(Asp-398) concatemers on each experimental day was used to normalize all of
the data collected on that day. All four concatemeric constructs
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were tested in each experiment. In this way, any residual batchto-batch oocyte variation could be accounted for.
EC50 and IC50 values are presented as the mean ⫾ 95% confidence interval (CI). Data were analyzed using Student’s t test
to compare pairs of groups or by one-way or two-way ANOVA
and Tukey’s multiple comparison test to compare the means of
three or more groups (PRISM, GraphPad Software, Inc.).

RESULTS
Introduction of the ␣5 Subunit Produces ␣3␤4* Receptors
with Distinct Pharmacological Responses—In an initial experiment to assess if co-injection of ␣5 subunits altered functional
responses of ␣3␤4* nAChR, oocytes were injected with equal
amounts of ␣3 and ␤4 RNA (1:1 injection ratio) or with equal
amounts of ␣3, ␣4, and ␣5 RNA (1:1:1 injection ratio). The
concentration-response profiles of the resulting nAChR populations are illustrated in Fig. 2. The introduction of ␣5 significantly decreased ACh potency at the ␣3␤4* nAChR population
(Fig. 2A; from 59 M (CI, 54 – 65 M) to 172 M (CI, 158 –187
M; p ⬍ 0.05)) and approximately halved the maximum AChinduced nAChR function (data not shown due to normalization
in Fig. 2). In contrast, the introduction of ␣5 had no effect on
cytisine potency at ␣3␤4* nAChR (Fig. 2B; mean ␣3␤4 and
␣3␤4␣5 EC50 values, 21 M (CI, 18 –24.8 M) and 20.5 M (CI,
17.7–24 M), respectively; p ⬎ 0.05). However, the addition of
␣5 subunits significantly reduced relative cytisine efficacy when
compared with the internal, maximally effective, 1 mM ACh
control (Fig. 2B; ␣3␤4 (1:1) ⫽ 90.0 ⫾ 1.9% and ␣3␤4␣5 (1:1:1) ⫽
34.1 ⫾ 0.7%, p ⬍ 0.05). The ␣3␤4-only nAChR population also
VOLUME 287 • NUMBER 30 • JULY 20, 2012
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FIGURE 2. Concentrations response profiles for ␣3␤4␣5 nAChR expressed as loose subunits. Oocytes injected with RNA for ␣3, ␤4, and ␣5 subunits in a
1:1 or 1:1:1 ratio were perfused with nAChR agonists acetylcholine (10⫺5.5 to 10⫺2; n ⫽ 6) (A), cytisine (10⫺6.25 to 10⫺2.5; n ⫽ 6) (B), nicotine (10⫺6.25 to 10⫺2; n ⫽
6) (C), or the ␣3␤4 nAChR antagonist mecamylamine (10⫺8 to 10⫺4; n ⫽ 6) (D). Data points represent averages (⫾S.E.). Differences in drug potency and efficacy
between groups were analyzed using one-way ANOVA with Tukey’s post hoc comparison (see “Experimental Procedures”).

␣5(D398N) Effects on ␣3␤4 Nicotinic Receptor Function

differed slightly from the ␣3␤4␣5 population in sensitivity to
nicotine (21 M (CI, 18 –26 M) to 45 M (CI, 40 –51 M)
respectively; p ⬍ 0.001). Similar to the situation with cytisine,
introduction of the ␣5 subunit also reduced the relative efficacy
of nicotine (% of internal ACh control per oocyte ⫽ 89.8 ⫾ 2.2%
for ␣3␤4-nAChR compared with 48.7 ⫾ 1.2% for ␣3␤4␣5nAChR; p ⬍ 0.001). Most strikingly, introduction of the ␣5
subunit increased the sensitivity of ␣3␤4* nAChR to the noncompetitive antagonist mecamylamine by more than an order
of magnitude (␣3␤4-only IC50 ⫽ 5.5 M (CI, 4.4 – 6.7 M);
␣3␤4␣5 IC50 ⫽ 0.40 M (CI, 0.38 – 0.49 M); p ⬍ 0.0001).
Effects of Common (Asp-398) and Risk (Asn-398) Variant ␣5
Subunit Integration into Concatenated ␣3␤4 Receptors—As
noted in the introduction, ␣5 subunits could potentially affect
nAChR function in a variety of ways. These could include “competition” with ␤4 subunits for incorporation into assembled
nAChR (29) and/or trapping as dead end intermediates of subunits that might otherwise assemble into functional nAChR
(30). Self-assembly of individual nAChR subunits could also
result in mixed populations of ␣3␤4 and ␣3␤4␣5 nAChR subtypes, possibly in proportions that vary between individual
oocytes. To remove these confounds, we designed pentameric
concatemers that enforce precise subunit ratios and assembly
orders. The resulting constructs encoded functional nAChR as
(␣3␤4)2␣5(Asn-398) and (␣3␤4)2␣5(Asp-398) forms. We also
produced concatemers as (␣3␤4)2␤4 and (␣3␤4)2␣3 isoforms
JULY 20, 2012 • VOLUME 287 • NUMBER 30

for comparison to concatemers containing ␣5 subunits. These
constructs are displayed schematically in Fig. 1A.
No significant differences in agonist sensitivity (EC50) were
observed among concatemers when ␤4, ␣3, or ␣5 nAChR subunits were present in the 5th pentameric position (Fig. 3A; p ⬎
0.05). In fact, EC50 values for multiple agonists were similar
across each of the concatemeric constructs and to those measured for ␣3␤4␣5 nAChR assembled from individual subunits at
1:1:1 cRNA ratios (Fig. 3A-C, Table 1; ACh, p ⬎ 0.05; cytisine,
p ⬎ 0.05; nicotine, p ⬎ 0.05).
Cytisine consistently demonstrated partial agonism across
the concatemeric ␣3␤4* nAChR constructs (Fig. 3B). The
efficacy of cytisine (normalized to responses to 1 mM ACh)
was indistinguishable between (␣3␤4)2␣5(Asp-398) and
(␣3␤4)2␣5(Asn-398) concatemers (25.5 ⫾ 0.6 to 27.3 ⫾ 0.5%;
respectively; p ⬎ 0.05). However, cytisine efficacy was significantly reduced at (␣3␤4)2␤4 tethered pentamers (Fig. 3B;
19.1 ⫾ 0.8%; p ⬍ 0.001) and still further at (␣3␤4)2␣3
constructs (Fig. 3B; 6.0 ⫾ 0.3%; p ⬍ 0.001). Similarly, nicotine
consistently demonstrated partial agonism across the set of
concatemeric ␣3␤4* nAChR constructs but evoked progressively weaker responses (as a % of 1 mM ACh control responses)
in oocytes expressing (␣3␤4)2␣5(Asp-398) (57.4 ⫾ 2.7%) or
(␣3␤4)2␣5(Asn-398) (53.5 ⫾ 2.5%) assemblies as opposed to
(␣3␤4)2␤4 (43.3 ⫾ 2.6%) or (␣3␤4)2␣3 (26.6 ⫾ 1.7%) concatemers (Fig. 3C; latter two reductions p ⬍ 0.001). Overall, the
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 3. Positional effects and functional sensitivity of concatenated ␣3, ␤4, ␣5(Asp-398) and ␣5(Asn-398) nAChR subunits. Concentration response
curves were generated for linked ␣3␤4 nAChR containing ␤4 at position 5 (open circles), ␣3 at position 5 (open boxes), ␣5(Asp-398) variant at position 5 (filled
circles), and ␣5(Asn-398) variant at position 5 (filled boxes). Concentration response curves were generated for known ␣3␤4 nAChR agonists acetylcholine
(␣3␤4)2(␤4); n ⫽ 16; (␣3␤4)2(␣3); n ⫽ 11; (␣3␤4)2␣5(Asp-398); n ⫽ 17; (␣3␤4)2␣5(Asn-398); n ⫽ 17) (A), cytisine (␣3␤4)2(␤4); n ⫽ 6; (␣3␤4)2(␣3); n ⫽ 6;
(␣3␤4)2␣5(Asp-398); n ⫽ 10; (␣3␤4)2␣5(Asn-398); n ⫽ 10) (B), and nicotine (␣3␤4)2(␤4); n ⫽ 6; (␣3␤4)2(␣3); n ⫽ 6; (␣3␤4)2␣5(Asp-398); n ⫽ 8; (␣3␤4)2␣5(Asn398); n ⫽ 8) (C). D, concentration response curves were also obtained using the ␣3␤4 antagonist, mecamylamine (␣3␤4)2(␤4); n ⫽ 6; (␣3␤4)2(␣3); n ⫽ 6;
(␣3␤4)2␣5(Asp-398); n ⫽ 8; (␣3␤4)2␣5(Asn-398); n ⫽ 8). Data points represent averages (⫾S.E.). For cytisine, nicotine, and mecamylamine, comparisons were
made by normalizing current responses as % 1 mM ACh (see “Experimental Procedures”). Differences in drug potency and efficacy between groups were
analyzed using one-way ANOVA with Tukey’s post hoc comparison (see “Experimental Procedures”).

␣5(D398N) Effects on ␣3␤4 Nicotinic Receptor Function
TABLE 1
Pharmacological parameters calculated from concatemeric ␣3␤4* nAChR and from ␣3␤4␣5 nAChR expressed from loose subunits

Oocytes injected with RNA encoding either concatenated ␣3␤4* nAChR or single ␣3, ␤4, and ␣5 subunits in a 1:1:1 ratio were perfused with the nAChR agonists
acetylcholine (10⫺6 to 10⫺2 M), cytisine (10⫺6.25 to 10⫺3 M), nicotine (10⫺6.5 to 10⫺3.5 M), or the nAChR antagonist mecamylamine (10⫺7.5 to 10⫺4 M). Data are presented as
the mean ⫾ S.E., with numbers of individual oocytes tested (n) as indicated. * denotes concatemeric constructs.
Acetylcholine

Cytisine

Nicotine

Mecamylamine

Expressed nAChR

n

Log EC50

nH ⴞ S.E.

n

Log EC50

nH ⴞ S.E.

n

Log EC50

nH ⴞ S.E.

n

Log IC50

nH ⴞ S.E.

␤4␣3␤4␣3␤4*
␤4␣3␤4␣3␣3*
␤4␣3␤4␣3␣5(Asp-398)*
␤4␣3␤4␣3␣5(Asn-398)*
␣3␤4␣5 (1:1:1)

16
11
17
17
6

⫺3.9 ⫾ 0.02
⫺4.0 ⫾ 0.03
⫺4.0 ⫾ 0.01
⫺4.0 ⫾ 0.02
⫺3.8 ⫾ 0.02

1.8 ⫾ 0.11
1.4 ⫾ 0.13
1.6 ⫾ 0.06
1.6 ⫾ 0.09
1.6 ⫾ 0.10

6
6
10
10
6

⫺4.8 ⫾ 0.07
⫺4.7 ⫾ 0.04
⫺4.8 ⫾ 0.04
⫺4.8 ⫾ 0.03
⫺4.7 ⫾ 0.03

1.6 ⫾ 0.4
1.2 ⫾ 0.12
1.3 ⫾ 0.15
1.3 ⫾ 0.13
1.5 ⫾ 0.2

6
6
8
8
6

⫺4.2 ⫾ 0.07
⫺4.1 ⫾ 0.07
⫺4.2 ⫾ 0.05
⫺4.3 ⫾ 0.06
⫺4.4 ⫾ 0.03

1.6 ⫾ 0.4
1.8 ⫾ 0.4
1.8 ⫾ 0.4
1.9 ⫾ 0.4
2.0 ⫾ 0.2

6
6
8
8
6

⫺7.4 ⫾ 0.04
⫺6.7 ⫾ 0.03
⫺6.2 ⫾ 0.03
⫺6.0 ⫾ 0.03
⫺6.4 ⫾ 0.02

⫺0.9 ⫾ 0.05
⫺1.1 ⫾ 0.08
⫺1.1 ⫾ 0.08
⫺1.2 ⫾ 0.08
⫺1.5 ⫾ 0.09
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FIGURE 4. ␣3␤4␣5 concatemers are expressed as functional pentamers
and are not byproducts of fractional assembly. A, co-injection (1:1:1) of
loose ␣3 and ␤4 nAChR subunits with the ␣5 gain of function subtype (V9⬘S)
enhances receptor function (p ⬍ 0.01; n ⫽ 4 oocytes per group). B, overexpression of the ␣5(V9⬘S) subunit has no effect on (␣3␤4)2(␤4) concatemer
function (n.s.; n ⫽ 4 oocytes per group). Panels A and B represent normalized
currents (% of ␣3␤4 (1:1) or ␤4(p5), respectively. Normalized currents were
analyzed using one-way ANOVA (see “Experimental Procedures”).

allows these comparisons to be made without uncertainty
related to the subunit makeup of the functional receptors.
However, efficiency of functional nAChR expression varies
across oocyte preparations and as a function of time post-injection. To compensate for this form of variation, we used a batchto-batch normalization strategy (described in detail under
“Experimental Procedures”).
As shown in Fig. 5A, peak ACh responses mediated by
(␣3␤4)2␣5(Asn-398) concatemers were significantly lower
than those evoked by stimulation of (␣3␤4)2␣5(Asp-398) concatemers (p ⬍ 0.001). Thus, although no differences in ACh
potency were observed between ␣3␤4* nAChR containing the
␣5(Asp-398) and ␣5(Asn-398) variants (as measured by their
EC50 values; see Fig. 3A), significant differences were observed
in levels of receptor function (as measured by current magnitudes; Fig. 5A). Similar trends were observed when absolute
levels of function were measured in response to maximally effiVOLUME 287 • NUMBER 30 • JULY 20, 2012
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presence of an ␣5 subunit in the concatemers resulted in
expression of nAChR with increased partial agonist efficacy by
cytisine and nicotine compared with that for actions at non-␣5
␣3␤4* concatemeric nAChR.
In contrast, the potency of the non-competitive antagonist mecamylamine decreased significantly on the order
(␣3␤4)2␤4 ⬎ (␣3␤4)2␣3 ⬎ (␣3␤4)2␣5 (Fig. 3D, Table 1; p ⬍
0.0001). However, no significant differences in IC50 values were
observed between (␣3␤4)2␣5(D398) and (␣3␤4)2␣5(N398)
concatemers (p ⬎ 0.05). Again, the mecamylamine IC50 values
recorded from ␣3␤4␣5 nAChR were very similar regardless of
whether these nAChR were assembled from individual subunits or from concatemeric constructs (see last three lines of
Table 1).
Only Intact nAChR Concatemers Contribute to Recorded
Function—In some cases, the covalent linkers within concatemeric constructs have been observed to break down. This liberates smaller products that can assemble to form functional
byproducts (4, 34, 35). To determine if this potential confound
was present in our system, the ␣5(V9⬘S) “gain-of-function”
mutant was coinjected with either a concatemeric construct
(␣3␤4)2␤4 or with individual ␣3 and ␤4 nAChR subunits.
Assembly of the ␣5(V9⬘S) subunit with either single subunits or
abridged concatemers would result in a substantial gain of
function (34, 36). Co-expression of ␣5(V9⬘S) with unlinked ␣3
and ␤4 subunits produced a significant increase in function
(peak current amplitude elicited by 1 mM ACh; Fig. 4A). This
demonstrates that the ␣5(V9⬘S) subunit can assemble with nonlinked subunits as predicted. As previously noted, co-injection
of a non-gain-of-function ␣5 subunit at a 1:1:1 ratio approximately halves ␣3␤4* function. This suggests that comparing
nAChR function between oocytes injected with ␣3 and ␤4 subunits at a 1:1 ratio to that after injection with ␣3, ␤4, and
␣5(V9⬘S) subunits at a 1:1:1 ratio may underestimate the effect
of the gain-of-function mutation. In contrast, co-injection of
the ␣5(V9⬘S) subunit with the concatemeric construct, even at a
3:1 ␣5(V9⬘S):concatemer ratio, produced no change in function
(Fig. 4B). These data demonstrate that at least the great majority of nAChR function arising from injection of the concatemeric construct mRNAs must be mediated by intact, pentameric nAChR concatemers.
Absolute Efficacy Comparisons between (␣3␤4)2␣5(Asp-398)
and (␣3␤4)2␣5(Asn-398) nAChR Concatemers—The studies
above describe partial agonist efficacies normalized to ACh.
However, we wanted to compare absolute agonist efficacies
between constructs containing either the ␣5(Asp-398) or
␣5(Asn-398) variants. The use of concatemeric constructs
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FIGURE 5. Maximum function comparison between (␣3␤4)2␣5(Asp-398) and (␣3␤4)2␣5(Asn-398) nAChR concatemers. Maximal currents (normalized
to (␣3␤4)2␣5(Asp-398); see “Experimental Procedures”) were compared between ␣3␤4 and ␣3␤4␣5-containing concatemers for acetylcholine (A); panels
A1–A4 represent averaged traces for ACh doses (10⫺6 to 10⫺2.25) for (␣3␤4)2(␤4) (n ⫽ 16), (␣3␤4)2(␣3) (n ⫽ 11), (␣3␤4)2␣5(Asn-398) (n ⫽ 17), and
(␣3␤4)2␣5(Asp-398) (n ⫽ 17), respectively. Peak ACh responses mediated by (␣3␤4)2␣5(Asn-398) concatemers were significantly lower than those of evoked
by stimulation of (␣3␤4)2␣5(Asp-398) concatemers (p ⬍ 0.001). Maximal currents were also compared between ␣3␤4 and ␣3␤4␣5 containing concatemers for
cytisine (B); panels B1–B4 represent averaged traces for cytisine doses (10⫺6.25 to 10⫺3) for (␣3␤4)2(␤4) (n ⫽ 6), (␣3␤4)2(␣3) (n ⫽ 6), (␣3␤4)2␣5(Asn-398) (n ⫽ 10),
and (␣3␤4)2␣5(Asp-398), (n ⫽ 8), respectively. However, peak cytisine responses mediated by (␣3␤4)2␣5(Asn-398) concatemers were not significantly lower
than those of evoked by stimulation of (␣3␤4)2␣5(Asp-398) concatemers (p ⬎ 0.05). Additionally, comparisons were made between concatemers for nicotine
(C); panels C1–C4 represent averaged traces for nicotine doses (10⫺6.25 to 10⫺3) for (␣3␤4)2(␤4) (n ⫽ 6), (␣3␤4)2(␣3) (n ⫽ 6), (␣3␤4)2␣5(Asn-398) (n ⫽ 8), and
(␣3␤4)2␣5(Asp-398) (n ⫽ 8), respectively. Again, no differences in peak nicotine responses were observed between (␣3␤4)2␣5(Asn-398)-containing concatemers and (␣3␤4)2␣5(Asp-398)-containing concatemers (p ⬎ 0.05). Maximum responses recorded from (␣3␤4)2(␤4) and (␣3␤4)2(␣3) nAChR were much smaller
than those measured from oocytes expressing either of the ␣5 variant constructs (p ⬍ 0.001). Comparisons between groups were analyzed using one-way
ANOVA with Tukey’s post hoc comparison (see “Experimental Procedures”).

cacious concentrations of cytisine (Fig. 5B; 300 M) or nicotine
(Fig. 5C; 300 M), although in neither case did these apparent
differences attain statistical significance (p ⬎ 0.05).
One of the more striking findings was that for each agonist the maximum responses recorded from (␣3␤4)2␣3 or
(␣3␤4)2␤4 nAChR were much smaller than those measured
from oocytes expressing either of the (␣3␤4)2␣5 variant conJULY 20, 2012 • VOLUME 287 • NUMBER 30

structs (Figs. 5, A–C; see Table 3). Peak currents were indistinguishable between (␣3␤4)2␣3 and (␣3␣4)2␣4 nAChR for each
agonist. This increased function for ␣5-containing concatemers is the opposite of the decreased function observed previously when ␣5 subunits are co-injected with unlinked ␣3 and
␤4 subunits. This observation may indicate that enforcing correct assembly of ␣5 subunits by use of a concatemeric construct
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reduces inefficiencies of assembly or the formation “dead-end
intermediates” that have previously been observed when
attempting to use self-assembly of individual subunits (30).
Divergent ␣3:␤4 RNA Injection Ratios Produce nAChR with
Different Functional Properties—As previously noted, pharmacological parameters measured for ␣3␤4␣5 nAChR were very
similar regardless of whether they were expressed from loose
subunits or from concatemeric constructs. The same was not
true, however, for ␣3␤4-only subtypes expressed from single
subunits injected at a 1:1 ratio or as concatemers (Figs. 2 and 3).
It has recently been noted that oocytes injected with different
␣3:␤4 mRNA ratios express ␣3␤4 nAChR populations with differing pharmacological properties (27, 28). By analogy to more
extensively studied high and low agonist sensitivity ␣4␤2
nAChR isoforms, it has been speculated that these populations
may correspond to (␣3␤4)2␤4 and (␣3␤4)2␣3 stoichiometries
(27, 28) as expressed by the concatemeric constructs produced
in this study.
The pharmacological properties of nAChR arising from coinjection of ␣3 and ␤4 subunits at 1:20 and 20:1 ratios are very
different (Fig. 6). Oocytes injected with ␣3␤4 in a 20:1 cRNA
injection ratio expressed receptors that were less sensitive to
ACh than those injected with ␣3␤4 in a 1:20 cRNA injection
ratio (Fig. 6A; EC50 values of 210 M (CI, 199 –218 M) versus 50
M (CI, 43–57 M), respectively; p ⬍ 0.0001). Cytisine concentration response profiles also differed, yielding lower sensitivity
responses for nAChR in oocytes injected with 20:1 ␣3:␤4 subunit cRNAs (Fig. 6B, EC50 ⫽ 63 M; CI, 54 –74 M) when
compared with those injected with 1:20 subunit ratios (Fig. 6B,
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EC50 ⫽ 8.6 M; CI, 6.7 to 11 M; p ⬍ 0.01). In addition, cytisine
efficacy (normalized to 1 mM ACh) was 2.3⫻ greater for oocytes
injected with ␣3:␤4 cRNAs at a 20:1 ratio than for oocytes
injected with a 1:20 cRNA ratio (Fig. 6B, 266.5 ⫾ 7.5 to 115.3 ⫾
2.5%, respectively; p ⬍ 0.0001). Moreover, nicotine EC50 values
and normalized efficacy values were lower for oocytes injected
with ␣3:␤4 subunit cRNAs in a 1:20 ratio than in a 20:1 ratio
(Table 2; 25 M (CI, 20 –33 M) to 46 M (CI, 39 –55 M)
respectively, p ⬍ 0.05). Nicotine was more efficacious for
oocytes injected with ␣3:␤4 cRNAs at a 20:1 ratio than for
oocytes injected with a 1:20 cRNA ratio (Fig. 6C, 151.9 ⫾ 5.4%
compared with 95.1 ⫾ 8.2% of 1 mM ACh control, respectively;
p ⬎ 0.01). Finally, oocytes injected with ␣3:␤4 cRNA at a 20:1
ratio were more sensitive to antagonism by mecamylamine
than oocytes injected at a 1:20 ratio (Fig. 6D, 0.12 M (CI, 0.07–
0.18 M) to 0.89 M (CI, 0.8 –1.0 M) respectively, p ⬍ 0.001).
Overall, the pharmacological properties measured from
oocytes injected with ␣3:␤4 cRNAs in a 1:1 or a 1:20 ratio more
closely resembled each other than those recorded from oocytes
injected at a 20:1 ratio (Table 3). The very similar properties of
nAChR arising from 1:1 or 1:20 ␣3:␤4 mRNA injection ratios
indicate that the same subunit assembly pattern predominates
in both cases. This confirms previous reports that Xenopus
oocytes injected with 1:1 and 1:9 ␣3:␤4 mRNA ratios express
similar ␣3␤4 nAChR populations, whereas high ␣3:␤4 mRNA
injection ratios result in expression of a distinctly different
␣3␤4 nAChR isoform (27, 28). However, none of the outcomes
observed from oocytes injected with any ratio of ␣3:␤4 mRNAs
closely resembled the results obtained from the concatemeric
VOLUME 287 • NUMBER 30 • JULY 20, 2012
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FIGURE 6. Concentration response profiles for ␣3␤4-only nAChR expressed as loose subunits. Oocytes injected with RNA for ␣3 and ␤4 subunits in a 1:20
or 20:1 ratio were perfused with nAChR agonists acetylcholine (10⫺6 to 10⫺2, n ⫽ 4) (A), cytisine (10⫺6.25 to 10⫺3; n ⫽ 4) (B), nicotine (10⫺6.5 to 10⫺3.5; n ⫽ 4) (C),
or the nAChR antagonist mecamylamine (10⫺7.5 to 10⫺4; n ⫽ 4) (D). Data points represent averages (⫾S.E.). Differences in drug potency and efficacy between
groups were analyzed using one-way ANOVA with Tukey’s post hoc comparison (see “Experimental Procedures”).

␣5(D398N) Effects on ␣3␤4 Nicotinic Receptor Function
TABLE 2
Agonist efficacies compared between concatemeric (␣3␤4)2X nAChR, where X is either ␤4, ␣3, ␣5(Asn-398) or ␣5 (Asp-398)

Maximal currents (normalized to (␣3␤4)2␣5(Asp-398); see “Experimental Procedures”) were compared between ␣3␤4* nAChR concatemers for acetylcholine (10⫺6 to
10⫺2.25 M), cytisine (10⫺6.25 to 10⫺3 M), and nicotine (10⫺6.25 to 10⫺3 M). Data are presented as the mean ⫾ S.E., with numbers of individual oocytes tested (n) as indicated.
Compound

n (␣3␤4)2␤4(% of Asp-398) n (␣3␤4)2␣3(% of Asp-398) n (␣3␤4)2␣5(Asn-398)(% of Asp-398) n (␣3␤4)2␣5(Asp-398) concatemer

Acetylcholine 16 11 ⫾ 1.0
Cytisine
6 5 ⫾ 1.0
Nicotine
6 11 ⫾ 4.0

11 9 ⫾ 1.0
6 6 ⫾ 1.0
6 9 ⫾ 3.0

17 63 ⫾ 7.0
10 80 ⫾ 11.0
8 85 ⫾ 9.0

17 100 ⫾ 5.0
10 100 ⫾ 14.0
8 100 ⫾ 4.0

TABLE 3
Pharmacological parameters calculated from ␣3␤4-only nAChR expressed from different injected subunit ratios

Oocytes injected with RNA for ␣3 and ␤4 subunits in a 1:1, 1:20, or 20:1 molar ratio were perfused with the nAChR agonists acetylcholine (10⫺6 to 10⫺2 M), cytisine (10⫺6.25
to 10⫺3 M), nicotine (10⫺6.5 to 10⫺3.5 M), or the nAChR antagonist mecamylamine (10⫺7.5 to 10⫺4 M). Data are presented as the mean ⫾ S.E., with numbers of individual
oocytes tested (n) as indicated.
Acetylcholine

Cytisine

Nicotine

Mecamylamine

Expressed nAChR

n

Log EC50

nH ⴞ S.E.

n

Log EC50

nH ⴞ S.E.

n

Log EC50

nH ⴞ S.E.

n

Log IC50

nH ⴞ S.E.

␣3␤4 (1:1)
␣3␤4 (1:20)
␣3␤4 (20:1)

6
4
4

⫺4.2 ⫾ 0.02
⫺4.3 ⫾ 0.02
⫺3.7 ⫾ 0.01

1.3 ⫾ 0.07
0.96 ⫾ 0.07
1.8 ⫾ 0.06

6
4
4

⫺4.7 ⫾ 0.03
⫺5.1 ⫾ 0.05
⫺4.2 ⫾ 0.03

1.3 ⫾ 0.13
1.1 ⫾ 0.13
1.5 ⫾ 0.14

6
4
4

⫺4.7 ⫾ 0.04
⫺4.6 ⫾ 0.05
⫺4.3 ⫾ 0.04

1.3 ⫾ 0.14
1.3 ⫾ 0.17
2.2 ⫾ 0.3

6
4
4

⫺5.3 ⫾ 0.04
⫺6.0 ⫾ 0.03
⫺6.9 ⫾ 0.1

⫺1.4 ⫾ 0.18
⫺1.2 ⫾ 0.1
⫺1.2 ⫾ 0.14

DISCUSSION
The pentameric concatemer approach allows accurate and
consistent reproduction of complex nAChR subtypes, with
complete control over subunit ratios and associations (5, 31, 38,
39). It also allows for mutagenesis of a single subunit within an
entire nAChR complex even where multiple copies of the target
subunit may be present. These unique advantages were central
to the work presented in this study. Using concatemeric
␣3␤4␣5 nAChR, we show that ␣5 subunit risk variant (Asn398) incorporation reduces ACh-evoked function when compared with inclusion of the ␣5 common variant (Asp-398).
Coexpression of unlinked ␣3, ␤4, and ␣5 subunits enforces
assembly of an apparently uniform nAChR population with
very similar pharmacological properties to those of concatemeric ␣3␤4* nAChR. In addition, either variant of the ␣5 subunit is capable of reducing the overall amount of ␣3␤4* nAChR
function after coinjection with non-concatenated ␣3 and ␤4
subunits. Further observations suggested that removing the
constraints imposed by either concatemerization or by co-expression with unlinked ␣5 subunits allows loose ␣3 and ␤4 subunits to assemble into at least two further subtypes. These
JULY 20, 2012 • VOLUME 287 • NUMBER 30

␣3␤4-only subtypes have substantially different pharmacological profiles from each other, from unlinked subunit ␣3␤4␣5
nAChR, and from any of the concatenated ␣3␤4 or ␣3␤4␣5
nAChR.
Critically, the pharmacological properties of ␣3␤4␣5 nAChR
expressed using pentameric concatemers were similar to those
of the same subtype expressed from unlinked subunits. This
finding indicates that the addition of the concatemeric linkers
did not noticeably alter nAChR function. It also reinforces further that pentameric concatemers faithfully replicate the ligand
sensitivity of the equivalent subunit arrangement when formed
from loose subunits. It has been suggested that ␣5 subunits
compete with ␤4 subunits (20, 29), reducing expression of functional ␣3␤4␣5 nAChR, possibly by encouraging the formation
of dead-end intermediates that become trapped inside the cell
(30). Our observations support this concept. Coinjection of
non-concatenated ␣5 subunit mRNA approximately halved
␣3␤4* functional expression in Xenopus oocytes compared
with injection of loose ␣3 and ␤4 subunits only (1:1:1 or 1:1
ratios were used; see the legend to Fig. 2). In contrast, if the ␣5
subunit is forced by concatemerization to assemble only as part
of a pentameric nAChR complex, its incorporation substantially increases functional expression (Fig. 5). Together, these
observations suggest that a reduction in function is not caused
by the incorporation of ␣5 subunits per se. Instead, the presence
of loose ␣5 subunits likely adversely affects the efficiency of
unlinked ␣3 and ␤4 nAChR subunit assembly into functional
nAChR.
In contrast, ␣3␤4-only nAChR expressed from pentameric
concatemers had different pharmacological properties from
those expressed from loose subunits (Table 1, top two rows, and
Table 2). This discrepancy could be explained in several ways.
One possibility is that covalent linkers may alter the properties
of concatemeric nAChR by constraining structural transitions
that are essential for normal function. This concern is mitigated
by previous publications (5, 31, 38, 39) indicating that well
designed pentameric nAChR concatemers can accurately
reproduce the properties of multiple native nAChR subtypes
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constructs or after co-injection of single ␣3, ␤4, and ␣5 subunits (Table 1). We conclude that the presence of an ␣5 subunit
or the use of concatemeric constructs results in the assembly of
functional nAChR with similar pharmacological properties.
These properties are likely the hallmark of assembly into a format containing two (␣3/␤4) subunit interfaces, with the addition of a fifth subunit in a non-ligand binding role. This conclusion is supported by a very recent study showing similar
pharmacological profiles of (␣3␤4)2X nAChR assembled from
␣3-␤4 dimeric concatemers with the addition of single ␣3, ␤4,
or ␣5 subunits (37). Without the constraints imposed by the
concatemeric linkers or by the need to integrate a non-ligand
binding ␣5 subunit, it seems possible that ␣3 and ␤4 subunits
are free to assemble into at least two other formats. The relative
proportions of the two formats expressed in the Xenopus oocyte
system can be altered by biasing the ␣3:␤4 nAChR subunit
mRNA injection ratio.
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these concatemers would have similar pharmacological profiles
to ␣3␤4-only nAChR formed after injection of loose ␣3 and ␤4
subunits at 1:20 and 20:1 ratios, respectively. However, the
pharmacology observed after injection of loose ␣3 and ␤4 subunits at either 1:20 or 20:1 ratios (Fig. 6, Table 2) was strikingly
different from the concatemeric “(␣3␤4)2X-type” measurements. The precise arrangements adopted by loose ␣3 and ␤4
subunits injected at different ratios remain unknown. It certainly seems probable that 1:20 and 20:1 ␣3:␤4 injection ratios
may give rise to nAChR with different stoichiometries (27, 28).
In addition, as demonstrated for GABAA receptors, the precise
order of subunit incorporation (even for identical subunit stoichiometries) can affect receptor function (42). The emerging
awareness that agonist binding to non-canonical nAChR interfaces can strongly affect function underlines this point (5, 41,
43). Determining whether different ␣3:␤4 subunit mRNA
injection ratios produce nAChR with different stoichiometries,
different arrangements of the same subunit stoichiometries, or
both will require a great deal more investigation. The concatemeric pentamer approach is uniquely well suited to addressing
this question.
Unlike agonist EC50 values, IC50 values for mecamylamine
inhibition were greatly affected by the identity of the fifth
subunit in each pentameric concatemer. This suggests that
mecamylamine (a non-competitive antagonist) interacts with
the resulting nAChR in a position where it can be influenced by
the presence of alternate subunits in the fifth, non-agonistbinding position. This sensitivity to ␣3␤4* nAChR composition
was also evident when comparing mecamylamine IC50 values
between ␣3␤4 and ␣3␤4␣5 nAChR expressed from loose
subunits (Table 1). These observations indicate that noncompetitive ligands may provide the best opportunities to
pharmacologically distinguish between different subunit
arrangements of ␣3␤4* isoforms. Importantly, this category
could also include positive allosteric modulators and/or allosteric agonists in addition to non-competitive antagonists.
Given the association of ␣5 subunit variants with a variety of
substance abuse behaviors (see introduction), selective manipulation of ␣3␤4␣5 nAChR activity could have valuable therapeutic implications.
Functional effects of the ␣5(D398N) mutation are hard to
distinguish without using a fully pentameric concatemer approach. The previously described effects of ␣5 subunits on
the efficiency of ␣3␤4* nAChR expression and possibly also
on subunit associations/assembly could outweigh and
obscure the effects of the ␣5(D398N) mutation. This could
explain previous studies’ conclusions that the effects of
␣5(Asp-389) incorporation were the same as those of
␣5(Asn-389) (18, 25, 37). However, using a pentameric
concatemer approach, we were able to compare the function of uniform populations of (␣3␤4)2␣5(Asp-389) versus
(␣3␤4)2␣5(Asn-389) nAChR. The maximum ACh-induced
function produced by (␣3␤4)2␣5(Asp-389) nAChR was significantly greater than that measured for (␣3␤4)2␣5(Asn389)
nAChR (Fig. 5). Increased function for ␣5(Asp-398)* versus
␣5(Asn-398)* nAChR with little difference in pharmacological
profile matches previous observations regarding ␣5 variant
incorporation into ␣4␤2* nAChR (11, 18).
VOLUME 287 • NUMBER 30 • JULY 20, 2012

Downloaded from http://www.jbc.org/ at ELSEVIER BV on September 19, 2019

(which assemble from unlinked subunits). In addition, the linkers in each of the pentameric concatemers used in this study are
of the same length and composition; it is unlikely that only the
non-␣5* concatemers used in this study would suffer from linker-induced functional alterations. Furthermore, if the non-␣5*
concatemers were uniquely affected by the presence of the linkers, it would be expected that this would strongly alter agonist
potencies and relative efficacies when compared with those of
the ␣5* concatemers. This is not the case; the pharmacological
parameters measured from all four of the concatemers tested
here are strikingly similar. A second possibility is that the covalent linkers within the concatemers might break down. This
would release sub-pentameric products that could assemble to
form unintended, but functional, byproducts (4, 34, 35). The
presence of such degradation products was checked for by coinjection with an ␣5(V9⬘S) mutant subunit. Assembly of this
mutant subunit with either single ␣3 and ␤4 subunits or subpentameric concatemers would result in a substantial gain of
function (34, 36). No change in function was noted when
␣5(V9⬘S) was co-injected with a concatemeric construct. This
confirms that all, or nearly all, of the function in oocytes
injected with pentameric nAChR mRNA constructs arises from
fully-pentameric concatemeric nAChR. Finally, and most
likely, the precise subunit associations imposed by concatemeric constructs may, or may not, correspond to those favored
during association of loose subunits. Our data suggest that the
␣3␤4␣5 concatemers accurately reproduce the conformation
adopted when the relevant individual subunits assemble freely.
However, the same is not true for the ␣3␤4-only constructs
when compared with nAChR assembled from loose ␣3 and ␤4
subunits. This would indicate that one role of the ␣5 subunit is
to impose a particular subunit composition on ␣3␤4* nAChR
expressed from loose subunits. If ␣5 is a true “accessory” subunit (i.e. does not interact directly with ligands), this may be
unavoidable; a (␣3␤4)2␣5 conformation is the only one in
which two pairs of ␣3⫹␤4 subunits would be available to provide agonist binding pockets and thus to assemble a functional
␣3␤4␣5 nAChR.
The preceding observations raise the question of which
nAChR subtype(s) is expressed after coinjection of only ␣3 and
␤4 subunits. This study confirms prior reports that at least two
␣3␤4 nAChR populations may be formed and that their relative
expression levels depend on the molar injection ratio of the
subunit mRNAs (1:20 versus 20:1). The pharmacology observed
in this study matches that reported in other recent publications
(27, 28) that used less-extreme injection ratios (1:9 versus 9:1 or
1:10 versus 10:1). The lack of further changes in observed pharmacology after adoption of more extreme subunit ratios indicates that, as for ␣4 and ␤2 subunits (2, 40, 41), relatively pure
populations of two different ␣3␤4 subunit assemblies are produced at the injection ratios used in this study. The same studies proposed again by analogy to the well-studied ␣4␤2 nAChR
that the different nAChR isoforms might correspond to
(␣3␤4)2␤4 and (␣3␤4)2␣3 nAChR (27).
Accordingly we constructed (␣3␤4)2␤4 and (␣3␤4)2␣3 concatemers using the same subunit arrangements as used successfully to encode high and low agonist sensitivity pentameric
␣4␤2 nAChR concatemers (5). We initially anticipated that
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It appears that, as previously proposed (20), ␣5 subunit
expression may act to modulate the amount of ␣3␤4* nAChR
function in the habenulopeduncular tract and in other tissues
that express ␣3␤4␣5 nAChR. This study indicates that the presence of the ␣5(Asp-398) or ␣5(Asn-398) variant will impose an
additional layer of functional modulation. As noted previously
(18), the concentrations of nicotine present in smokers are too
low to significantly activate or desensitize ␣3␤4␣5 nAChR.
However, the activity induced by synaptic or perisynaptic ACh
release onto ␣3␤4* nAChR could be strongly affected by the
integration of ␣5(Asp-398) or ␣5(Asn-398) subunits. This in
turn could result in compensatory changes either at the neurotransmitter/receptor level or at the circuit activity level,
which may explain some of the phenotypic variations attributed
to the ␣5(D398N) mutation. Given the established role of the
habenulopeduncular pathway ␣3␤4␣5 nAChR function in nicotine dependence and aversive behavior (20, 44, 45), it seems
likely that selective manipulation of ␣3␤4␣5 function mediated
by this subtype could represent a valuable smoking cessation
strategy. Our current findings indicate that non-competitive/
allosteric compounds may be the most promising category of
potential therapeutic agents for such an approach.
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